ClinicalTrials.gg
CompletedNCT00101335Updated Jul 11, 2013

Celecoxib in Preventing Head and Neck Cancer in Patients With Oral Leukoplakia

A Phase 2 interventional study of celecoxib in Head and Neck Cancer and Precancerous Condition, sponsored by Fox Chase Cancer Center. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-07-11.

Primary conditionLeukoplakia, OralRegistry: Head and Neck NeoplasmsReclassifiedWhy we changed it
Registry
Head and Neck Neoplasms — the first condition term the registry derived for this study.
ClinicalTrials.gg
Leukoplakia, Oral
Why
  1. The study's title name Leukoplakia, Oral, a narrower term within Head and Neck Neoplasms.
Confidence
High: the new condition is named in the study's own title. Of 46 hand-checked studies reclassified this way, 72% were exactly right and 89% in the right disease family; the registry's first term was right for 4% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Fox Chase Cancer Center · Phase 2, Interventional, and Prevention

Phase
Phase 2
Study type
Interventional
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-13

Among 20 studies in Leukoplakia, Oral with a site in United States — 1 open to participants now, 3 under way, none of them phase 3. Leukoplakia, Oral · United States.

Started
2003
with 3 others
Phase 2
11 of 20
1 open now
Registered
4th of 20
by date
Lead sponsor
1 of 20
Fox Chase Cancer Center

Among the 20 studies in Leukoplakia, Oral with a site in United States, this one is one of 4 that started in 2003, is one of 11 in phase 2, and was the 4th registered.

Leukoplakia, Oral

48 studies on the registry are indexed under Leukoplakia, Oral; 11 are open to participants now.

Browse Leukoplakia, Oral studies →

Open to participants now

1 of the 20 studies in Leukoplakia, Oral with a site in United States is open now. Recruiting first, the newest first:

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 7 Leukoplakia, Oral studies recruiting now, 5 set no upper age limit and none stop at 75 or younger; none take children under 18; 1 takes healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Watch this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies in Leukoplakia, Oral with a site in United States, or all of them as a file.
02

Study summary

RATIONALE: Chemoprevention is the use of certain drugs to keep cancer from forming, growing, or coming back. The use of celecoxib may prevent or treat head and neck cancer.

PURPOSE: This randomized phase II trial is studying celecoxib to see how well it works compared to placebo in preventing head and neck cancer in patients with oral leukoplakia.

Read the detailed description

OBJECTIVES:

Primary

  • Compare the clinical efficacy of celecoxib vs placebo, in terms of inducing regression of oral leukoplakia lesions, in patients with hyperplastic or dysplastic oral leukoplakia.

Secondary

  • Determine the effect of this drug in modulating multiple intermediate biomarkers (e.g., COX-2, PPARγ, or PPARδ) in normal and hyperplastic or dysplastic oral epithelia of these patients.
  • Determine the safety of this drug in these patients.
  • Determine the cost-effectiveness of this drug as a chemopreventative agent in these patients.

OUTLINE: This is a randomized, double-blind, placebo-controlled, cross-over study. Patients are stratified according to the pathology of the leukoplakia lesion (dysplasia vs hyperplasia). Patients are randomized to 1 of 2 arms.

  • Arm I: Patients receive oral celecoxib twice daily for 3 months.
  • Arm II: Patients receive oral placebo twice daily for 3 months. All patients undergo biopsy. Patients then cross-over to the opposite treatment arm for 3 months.

In both arms, treatment continues in the absence of unacceptable toxicity or disease progression.

Patients are followed at 1 month.

PROJECTED ACCRUAL: A total of 27-60 patients (18-40 for study drug, 9-20 for placebo before cross-over) will be accrued for this study.

03

Conditions studied

  • Head and Neck Cancer
  • Precancerous Condition

Keywords

  • hypopharyngeal cancer
  • lip and oral cavity cancer
  • nasopharyngeal cancer
  • oropharyngeal cancer
  • tongue cancer
  • oral leukoplakia
04

In context

Leukoplakia, Oral Reclassified

48 studies on the registry are indexed under Leukoplakia, Oral; 11 are open to participants now.

Browse Leukoplakia, Oral studies →

Lead sponsor

Fox Chase Cancer Center is the lead sponsor of 216 studies on the registry; 29 are open to participants now.

Of its 16 completed or terminated interventional studies of FDA-regulated products, 9 (56%) have results posted.

Compared within Leukoplakia, Oral, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Head and Neck Neoplasms. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

DISEASE CHARACTERISTICS:

  • Diagnosis of oral leukoplakia with hyperplasia or dysplasia

    • Documented by baseline of oral lesions suspicious for leukoplakia
    • For patients using dentures over the past 6 months, only lesions located on the ventral-lateral tongue or floor of the mouth are allowed
    • No leukoplakia/hyperplasia secondary to mechanical irritation
  • No carcinoma in situ of the oral cavity

PATIENT CHARACTERISTICS:

Age

  • 18 and over

Performance status

  • Not specified

  • At least 1 year

Hematopoietic

  • ≥ 10 g/dL (women) OR ≥ 11 g/dL (men)

Hepatic

  • or ALT normal
  • normal

Renal

  • Creatinine normal OR
  • ≥ 60 mL/min

Cardiovascular

  • No myocardial infarction within the past 12 months
  • No known active ischemic cardiac disease by stress test or echocardiogram

Gastrointestinal

  • No history of gastrointestinal hemorrhage
  • No known gastrointestinal ulcers within the past 2 years unless there is documentation of healed lesions by upper endoscopy
  • No active or suspected peptic ulcer disease
  • Negative stool guaiac test

Other

  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective during and for 2 months after study treatment
  • No use of snuff or chewing tobacco within the past 2 months
  • No active invasive within the past 3 years except nonmelanoma skin cancer or in situ carcinomas
  • No clinical evidence of chronic infectious disease
  • No clinical evidence of connective tissue disease
  • No known (asthma, urticaria, or acute rhinitis induced by NSAIDs) to aspirin or other NSAIDs
  • No known hypersensitivity to sulfonamides

PRIOR CONCURRENT THERAPY:

Biologic therapy

  • Not specified

Chemotherapy

  • Not specified

Endocrine therapy

  • At least 6 months since prior chronic or frequent use of systemic
  • No concurrent chronic or frequent use of systemic glucocorticoids

Radiotherapy

  • Not specified

Surgery

  • Not specified

Other

  • No prior chronic or frequent (> 100 mg per day aspirin equivalent) use of nonsteroidal anti-inflammatory drugs (NSAIDs) for 7 of the past 14 days
  • At least 3 months since prior experimental therapy
  • No concurrent chronic or frequent use of NSAIDs

    • Cardioprotective doses of aspirin ≤ 100 mg daily are allowed
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anaemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

06

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomized
Masking
Double

Interventions

07

Study locations

1 site
  • Fox Chase Cancer Center
    Philadelphia, Pennsylvania 19111-2497, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2003, a primary completion of Jan 2005 and a completion of Jan 2005. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 7, 2005
First posted
Jan 10, 2005
Start
Nov 2003
Primary completionActual
Jan 2005
CompletionActual
Jan 2005
Last update
Jul 11, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 11, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00101335
Responsible party
Sponsor
First posted
Jan 10, 2005
Start date
Nov 2003
Primary completion
Jan 2005
Completion
Jan 2005
Last update
Jul 11, 2013

Study contacts

Paul F. Engstrom, MD
principal investigator · Fox Chase Cancer Center

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Celecoxib

Start the discussion